Phreesia had its Relative Strength (RS) Rating upgraded from 62 to 73 Tuesday — a welcome improvement, but still below the 80 or better score you look for.
When To Sell Stocks To Lock In Profits And Minimize Losses
This unique rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the stocks that go on to make the biggest gains often have an 80 or better RS Rating in the early stages of their moves. See if Phreesia can continue to rebound and hit that benchmark.
Phreesia is trying to complete a consolidation with a 30.53 buy point. See if the stock can break out in heavy volume.
The company showed 0% earnings growth in its most recent report, while sales growth came in at 15%.
The company earns the No. 6 rank among its peers in the Computer Software-Medical industry group. Veeva Systems Cl A, OptimizeRx and Doximity are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
